EUVIMEDEUVIMED entdecken
Crossref

Tenascin-C induces transdifferentiation of retinal pigment epithelial cells in proliferative vitreoretinopathy

Tianyi Zong, Tong Mu, Chengye Tan, Tianhua Xie, Miao Zhuang, Yan Wang, Ziwen Li, Qian Yang, Meili Wu, Jiping Cai, Xiaolu Wang, Yong Yao

Experimental Eye Research · 2024

DOI: 10.1016/j.exer.2024.110097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Eye Research, 2024. Verfasst von Tianyi Zong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wu…. Hauptthemen laut MEDLINE: Tenascin, Vitreoretinopathy, Proliferative, Retinal Pigment Epithelium, Cell Transdifferentiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proliferation and transdifferentiation of the retinal pigment epithelium (RPE) are hallmarks of proliferative vitreoretinopathy (PVR); however, the critical regulators of this process remain to be elucidated. Here, we investigated the role of tenascin-C in PVR development. In vitro, exposure of human ARPE-19 (hRPE) cells to TGF-β2 increased tenascin-C expression. Tenascin-C was shown to be involved in TGF-β2-induced transdifferentiation of hRPE cells, which was inhibited by pretreatment with tenascin-C siRNA. In PVR mouse models, a marked increase in the expression of tenascin-C mRNA and protein was observed. Additionally, immunofluorescence analysis demonstrated a dramatic increase in the colocalization of tenascin-C with RPE65 or α-smooth muscle actin(α-SMA) in the epiretinal membranes of patients with PVR. There was also abundant expression of integrin αV and β-catenin in the PVR membranes. ICG-001, a β-catenin inhibitor, efficiently attenuated PVR progression in a PVR animal model. These findings suggest that tenascin-C is secreted by transdifferentiated RPE cells and promotes the development of PVR via the integrin αV and β-catenin pathways. Therefore, tenascin-C could be a potential therapeutic target for the inhibition of epiretinal membrane development associated with PVR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenascinVitreoretinopathy, ProliferativeRetinal Pigment EpitheliumCell TransdifferentiationDisease Models, AnimalAnimalsHumansMiceMice, Inbred C57BLCells, CulturedBlotting, WesternRNA, MessengerCell ProliferationMaleReal-Time Polymerase Chain ReactionGene Expression Regulation

Stichwörter der Autor:innen

Proliferative vitreoretinopathyRetinal pigment epithelial cellsTenascin-CTransdifferentiation

Substanzen

TenascinRNA, Messenger

Autor:innen und Institutionen

  • Department of Ophthalmology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi People's Hospital, 299 Qingyang Road, Wuxi, Jiangsu. 214023, People…
  • Center of Clinical Research, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi People's Hospital, 299 Qingyang Road, Wuxi, Jiangsu, 214023, People…

Zitieren

APA

Zong, T., Mu, T., Tan, C., Xie, T., Zhuang, M., Wang, Y., Li, Z., Yang, Q., Wu, M., Cai, J., Wang, X., & Yao, Y. (2024). Tenascin-C induces transdifferentiation of retinal pigment epithelial cells in proliferative vitreoretinopathy. Experimental Eye Research. https://doi.org/10.1016/j.exer.2024.110097

Vancouver

Zong T, Mu T, Tan C, Xie T, Zhuang M, Wang Y, et al. Tenascin-C induces transdifferentiation of retinal pigment epithelial cells in proliferative vitreoretinopathy. Experimental Eye Research. 2024. doi:10.1016/j.exer.2024.110097

BibTeX
@article{Zong2024,
  author = {Zong, Tianyi and Mu, Tong and Tan, Chengye and Xie, Tianhua and Zhuang, Miao and Wang, Yan and Li, Ziwen and Yang, Qian and Wu, Meili and Cai, Jiping and Wang, Xiaolu and Yao, Yong},
  title = {Tenascin-C induces transdifferentiation of retinal pigment epithelial cells in proliferative vitreoretinopathy},
  journal = {Experimental Eye Research},
  year = {2024},
  doi = {10.1016/j.exer.2024.110097}
}
Kostenlos starten →